Niclosamide Enema for Active Distal Ulcerative Colitis: A Phase 1, Open-Label Study
Inflammatory Bowel Diseases · 03.06.2024 · 30 (6) · 894-899
DOI: 10.1093/ibd/izad125 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 21.07.2023. Verfasst von Irene Marafini und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Niclosamide, Enema. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: First Wave BioPharma Inc..
Abstract (Originalsprache)
Background
Oral and rectal formulations of 5-aminosalicylic acid are the first-line therapy for mild-to-moderate, distal ulcerative colitis (UC), but such a treatment is not effective in one-third of patients. Niclosamide is a small molecule, developed and approved as an orally administered drug to treat helminthic infections, with an excellent safety profile. Preclinical work showed that niclosamide is an anti-inflammatory agent, thereby providing the rationale to explore its safety and efficacy in patients with UC. This phase 1, open-label trial was aimed at assessing the safety of niclosamide formulated as an enema in patients with mild-to-moderate, distal UC, who relapsed on maintenance therapy with oral and/or rectal 5-aminosalicylic acid.
Methods
Seventeen patients with active UC received niclosamide enema (150 mg/60 mL) twice a day for 6 weeks. The primary endpoint was the safety of niclosamide treatment. Secondary endpoints included clinical remission and improvements in endoscopic Mayo/histologic scores. Endoscopic remission percentages exclude participants meeting criteria at baseline for endoscopic remission.
Results
Niclosamide was well tolerated by all 17 patients that were enrolled and treated. No serious adverse event was registered. Fifteen mild adverse events were registered in 6 patients and considered to be unrelated to the treatment. Clinical remission was achieved in 10 (59%) of 17 patients. Improvements of endoscopic Mayo score and histologic Geboes score were seen in 7 (58%) of 12 and 7 (41.2%) of 17 patients, respectively.
Conclusions
Niclosamide enema treatment is safe and well tolerated. Niclosamide improves clinical symptoms and endoscopic/histologic signs of UC; however, appropriately designed placebo-controlled clinical trials are required to confirm efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
- Gastroenterology Unit, Policlinico Universitario Tor Vergata, Rome, Italy.
- University of Michigan, Ann Arbor, MI, USA.
- Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
- Department of Medicine, University of Verona, Verona, Italy.
ORCID-Profile: Giovanni Monteleone
Förderung
- First Wave BioPharma Inc.
Zitieren
APA
Marafini, I., De Cristofaro, E., Salvatori, S., Calabrese, E., Lolli, E., Monteleone, I., Franchi, L., Ciccocioppo, R., Glick, G., Opipari, A., & Monteleone, G. (2024). Niclosamide Enema for Active Distal Ulcerative Colitis: A Phase 1, Open-Label Study. Inflammatory Bowel Diseases, 30(6), 894-899. https://doi.org/10.1093/ibd/izad125
Vancouver
Marafini I, De Cristofaro E, Salvatori S, Calabrese E, Lolli E, Monteleone I, et al. Niclosamide Enema for Active Distal Ulcerative Colitis: A Phase 1, Open-Label Study. Inflammatory Bowel Diseases. 2024;30(6):894-899. doi:10.1093/ibd/izad125
BibTeX
@article{Marafini2024,
author = {Marafini, Irene and De Cristofaro, Elena and Salvatori, Silvia and Calabrese, Emma and Lolli, Elisabetta and Monteleone, Ivan and Franchi, Luigi and Ciccocioppo, Rachele and Glick, Gary and Opipari, Anthony and Monteleone, Giovanni},
title = {Niclosamide Enema for Active Distal Ulcerative Colitis: A Phase 1, Open-Label Study},
journal = {Inflammatory Bowel Diseases},
year = {2024},
volume = {30},
number = {6},
pages = {894--899},
doi = {10.1093/ibd/izad125}
}
EUVIMED